GNRH analogues for treatment of urinary incontinence

• US 7,498,303 B2
• Filed: 10/26/2001
• Issued: 03/03/2009
• Est. Priority Date: 10/30/2000
• Status: Expired due to Fees

• Current Assignee: University of Zuerich
• Original Assignee: University of Zuerich
• Inventors: Reichler, Iris, Arnold, Susi, Hubler, Madeleine
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): Cordero Garcia; Marcela M
• Application Number:
  US10/415,519
• Publication Number:
  US 20040023878A1
• Time in Patent Office: 2,685 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/12 for climacteric disorders

Abstract

The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed.

Claims

1. A method for the treatment of urinary incontinence in a female mammal in need thereof comprising administering an effective amount of at least one GnRH analogue to said female mammal wherein said GnRH analogue is deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, Cetrorelix or mixtures thereof.

2. A method according to claim 1 wherein at least said GnRH analogue is administered in a slow release formulation.

3. A method according to claim 1 wherein said treatment consists essentially of administering at least one GnRH analogue.

4. A method according to claim 1 wherein said female mammal is a human female pre-or postmenopausal, or a female dog.

5. A method according to claim 1 wherein said at least one GnRH analogue is administered as part of a formulation for subcutaneous administration.

6. A method according to claim 1 wherein said at least one GnRH analogue is administered as part of a formulation for parenteral, oral or rectal administration.

7. A method according to claim 1 wherein said at least one GnRH analogue is administered as part of a formulation for intranasal, transdermal or intravaginal administration.

8. A method according to claim 1 wherein said at least one GnRH analogue and a further active substance are administered in different unit forms.

9. A method according to claim 1 wherein a further active substance is administered to said female mammal, and wherein said substance is selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent and mixtures thereof.

10. A method according to claim 9 wherein said estrogenic agent is estradiol valerate, a conjugated equine estrogen, 17β

-estradiol, estrone or estriol;

the partial estrogenic agent is raloxifene, centchroman, toremifen or tamoxifen; and

the progestational agent is progesterone, hydroxygesterone, medroxyprogesterone, norethisterone, levonogestrel, norgestrel, gestodene or drospirenone.

11. A method according to claim 1 wherein a further active substance is administered to said female mammal, and wherein said active substance is alpha-adrenergic agonist, beta adrenergic receptor blocking agent, cholinergic receptor blocking compound, cholinergic receptor stimulating drug, smooth muscle relaxant, nitric oxide synthase substrate, a nitric oxide donor, or a mixture thereof.

18. A method according to claim 9 wherein said at least one GnRH analogue and said further active substance are administered in different unit forms.

12. A method for reducing the risk of urinary incontinence in a female mammal in need thereof comprising administering an effective amount of at least one GnRH analogue to said female mammal wherein said GnRH analogue is deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, Cetrorelix or mixtures thereof.

13. A method according to claim 12 wherein a further active substance is administered to said female mammal, and wherein said substance is selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent and mixtures thereof.

14. A method according to claim 13 wherein said estrogenic agent is estradiol valerate, a conjugated equine estrogen, 17β

-estradiol, estrone or estriol;

the partial estrogenic agent is raloxifene, centchroman, toremifen or tamoxifen; and

the progestational agent is progesterone, hydroxygesterone, medroxyprogesterone, norethisterone, levonogestrel, norgestrel, gestodene or drospirenone.

15. A method according to claim 12 wherein a further active substance is administered to said female mammal, and wherein said active substance is alpha-adrenergic agonist, beta adrenergic receptor blocking agent, cholinergic receptor blocking compound, cholinergic receptor stimulating drug, smooth muscle relaxant, nitric oxide synthase substrate, a nitric oxide donor, or a mixture thereof.

16. A method according to claim 12 wherein at least said GnRH analogue is administered in a slow release formulation.

17. A method according to claim 12 wherein said female mammal is a human female pre-or postmenopausal, or a female dog.